Hiebeler, Miriam
Thiele, Simone
Reilich, Peter
Bernert, Günther
Walter, Maggie C.
Funding for this research was provided by:
Universitätsklinik München
Article History
Received: 15 September 2022
Accepted: 29 December 2022
First Online: 5 January 2023
Competing interests
: Maggie C. Walter has served on advisory boards for Avexis, Biogen, Novartis, Pfizer, Roche, Santhera, Sarepta, Pharnext, PTC Therapeutics, Ultragenyx, Wave Sciences, received funding for Travel or Speaker Honoraria from Avexis, Biogen, PTC Therapeutics, Ultragenyx, Santhera, Sarepta, and worked as an ad-hoc consultant for AskBio, Audentes Therapeutics, Avexis, Biogen Pharma GmbH, Fulcrum Therapeutics, GLG Consult, Guidepoint Global, Gruenenthal Pharma, Novartis, Pharnext, PTC Therapeutics, Roche. Miriam Hiebeler has no competing interests. Simone Thiele has received financial support for advisory services from PTC. Günther Bernert has served on advisory boards for Avexis, Biogen, Novartis, Pfizer, Roche, Santhera, Sarepta, PTC Therapeutics, he received funding for Travel or Speaker Honoraria from Avexis, Biogen, Novartis, PTC Therapeutics, Roche and worked as an ad-hoc consultant for Biogen Pharma GmbH, PTC Therapeutics, and Roche. Peter Reilich has no competing interests.